19:42 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
22:07 , Oct 1, 2018 |  BC Extra  |  Clinical News

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
19:53 , Aug 13, 2018 |  BC Extra  |  Company News

Amicus prices Galafold at $315k per year

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation. On Friday,...
20:35 , Aug 10, 2018 |  BC Extra  |  Company News

Amicus' Galafold wins accelerated approval from FDA

FDA granted accelerated approval to Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD) to treat Fabry disease in adults who have amenable mutations. Amicus said the U.S. approval is the first for a new Fabry disease...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
19:14 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Avrobio proposes $86.3M NASDAQ IPO

Avrobio Inc. (Cambridge, Mass.) proposed on May 25 to raise $86.3 million in an IPO underwritten by Morgan Stanley, Cowen, Wells Fargo and Wedbush PacGrow. In February, the cell therapy company raised $60 million in...
22:08 , May 25, 2018 |  BC Extra  |  Financial News

Eidos, Avrobio propose NASDAQ IPOs

Eidos Therapeutics Inc. (Palo Alto, Calif.) and Avrobio Inc. (Cambridge, Mass.) proposed NASDAQ IPOs on Friday. Eidos proposed to raise $115 million in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays. Last...
15:38 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Japan approvals include Hemlibra, Shingrix Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc....
22:09 , Mar 23, 2018 |  BC Extra  |  Company News

Japan approvals include Hemlibra, Shingrix, Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc....